selective oral Wee1 kinase inh. (300 mg QD)

Ph. II candidate for uterine serous carcinoma

from literature starting point

Journal of Medicinal Chemistry

Zentalis Pharmaceuticals, San Diego, CA, USA

ZN-c3

The Zentalis Wee1 inhibitor, ZN-c3, is a highly selective kinase inhibitor that is currently being evaluated in Ph. II clinical trials in adult women with recurrent or persistent uterine serous…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: